Table 4.
Medication adherence and related factors.
| Medication Adherence (MA) | Weak | Average | High | Number |
|---|---|---|---|---|
| Total number [%] * | 2 [2.15%] | 31 [33.33%] | 60 [64.52] | 93 |
| MA by gender | ||||
| Men [%] | 0 [0] | 20 [41.67%] | 28 [58.33%] | 48 [51.61%] |
| Women [%] | 2 [4.44%] | 11 [24.44%] | 32 [71.11%] | 45 [48.39%] |
| MA vs. professional status | ||||
| Working [%] | 1 [2.56%] | 17 [43.59%] | 21 [53.85%] | 39 [41.93%] |
| Retired [%] | 1 [1.85%] | 14 [25.93%] | 39 [22.72%] | 54 [58.06%] |
| MA versus number of therapies | ||||
| Monotherapy [%] | 1 [1.97%] | 19 [33.93%] | 36 [29.64%] | 56 [60.22%] |
| Two therapies [%] | 1 [3.13%] | 10 [31.25%] | 21 [65.63%] | 32 [34.4%] |
| Three therapies [%] | 0 [0%] | 2 [40%] | 3 [60%] | 5 [5.38%] |
| Duration of the disease | ||||
| Up to 5 years [%] | 2 [5.71%] | 15 [42.86%] | 18 [51.43%] | 35 [37.63%] |
| 6–10 years [%] | 0 | 9 [37.50%] | 15 [62.50%] | 24 [25.81%] |
| 11–15 years [%] | 0 | 4 [20.00%] | 16 [80%] | 20 [21.51%] |
| 16–20 years [%] | 0 | 3 [30.00%] | 7 [70%] | 10 [10.75%] |
| over 21 years [%] | 0 | 0 | 4 [100%] | 4 [4.3%] |
| Number of comorbidities | ||||
| One concomitant disease [%] | 2 [7.14%] | 7 [25%] | 19 [67.86%] | 28 [30.10%] |
| Two additional concomitant diseases [%] | 0 | 14 [41.18%] | 20 [58.82%] | 34 [36.55%] |
| Three additional concomitant diseases [%] | 0 | 5 [25%] | 15 [75%] | 20 [21.50%] |
| Four additional concomitant diseases [%] | 0 | 3 [37.5%] | 5 [62.50%] | 8 [8.6%] |
| Five additional concomitant diseases [%] | 1 [33.33%] | 1 [33.33%] | 1 [33.33%] | 3 [3.22%] |
| Costs for treatment | ||||
| Paid by patients | 19.52 ± 2.1 | 32.89 ± 23.85 | 37.31 ± 25.56 | |
| Type of therapy | ||||
| Insulin secretagogues | 0 | 2 [16.67%] | 10 [83.3%] | 12 |
| metformin | 0 | 13 [43.3%] | 17 [56.67%] | 30 |
| Insulin secretagogues + metformin | 1 [8.3%] | 5 [41.6%] | 6 [50%] | 12 |
* The relative share of each absolute number is presented in brackets in percentages [%].